VEXAS is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. Given the variability in disease presentation & the limited number of studies to date, an international multidisciplinary panel of VEXAS experts was convened to provide guidance to healthcare providers on the condition’s management. We spoke to experts on the panel about the resulting guidance document.
In the ACR Convergence 2025 session, Great Debate: Ultrasound vs. Temporal Artery Biopsy in Giant Cell Arteritis, two vasculitis experts went head to head to determine the ideal first test in the diagnosis GCA: ultrasound or biopsy.
Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.
At this ACR Convergence 2025 session, experts discussed disease management considerations to optimize outcomes in pregnant patients with SLE.
Updating the last iteration in 1999, the new ACR Guideline for Management of SLE was unveiled at ACR Convergence 2025, providing rheumatologists an organ-based approach for therapeutic options for specific lupus manifestations.
At this ACR Convergence 2025 session, the speaker highlighted ways complementary and alternative medicine can be used alongside traditional medical treatments.
In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.
Ableism—discrimination against those with disabilities—distorts diagnostic reasoning & erodes patient trust. How can rheumatologists address this bias?
At a ACR Convergence 2025 session, two experts discussed POTS, the importance of considering dysautonomia when making a differential diagnosis & an interdisciplinary approach to treatment.
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.